2022年美国风湿病学会糖皮质激素诱导性骨质疏松症预防与治疗指南
该指南针对接受泼尼松等效剂量≥2.5 mg/日、疗程>3个月的糖皮质激素治疗的风湿性或非风湿性疾病患者,更新了糖皮质激素诱导性骨质疏松症(GIOP)的预防与治疗推荐。指南采用推荐分级的评估、制定与评价(GRADE)方法,由投票专家组达成≥70%共识,强烈推荐尽早评估骨折风险并对中、高、极高骨折风险成人进行药物治疗。
要点
- 成人开始或继续>3个月糖皮质激素治疗者,强烈推荐尽早行骨折风险评估、骨密度检测及椎体骨折评估或脊柱X线。
- 中、高、极高骨折风险成人强烈推荐药物治疗,药物选择包括双膦酸盐、地舒单抗或甲状旁腺激素类似物。
- 高、极高骨折风险者可考虑将合成代谢药物作为初始治疗(条件推荐)。
核心结论
- 该指南为临床医生和患者管理GIOP提供治疗决策方向,推荐不应被用于限制或拒绝治疗的可及性。
研究设计与样本
- 美国风湿病学会(ACR)制定,采用GRADE方法对证据确定性进行分级,投票专家组对推荐方向和强度达成≥70%共识。
主要发现
- 对开始或继续>3个月糖皮质激素治疗的成人,强烈推荐在启动糖皮质激素后尽快进行临床骨折评估、骨密度检测联合椎体骨折评估或脊柱X线,≥40岁者使用骨折风险评估工具(FRAX)。
- 对中、高、极高骨折风险成人,强烈推荐药物治疗;口服或静脉双膦酸盐、地舒单抗或甲状旁腺激素类似物的选择应通过共享决策制定。
- 对高和极高骨折风险者,条件推荐将合成代谢药物作为初始治疗。
- 指南还针对特殊人群(儿童、器官移植者、可能妊娠者及接受极高剂量糖皮质激素治疗者)给出推荐,并新增停药和序贯治疗推荐。
关键数值与推荐
- 强烈推荐:开始糖皮质激素后尽快行骨折风险评估(临床骨折评估、骨密度检测联合椎体骨折评估或脊柱X线),≥40岁者使用FRAX。
- 强烈推荐:中、高、极高骨折风险成人接受药物治疗。
- 条件推荐:高和极高骨折风险者可考虑合成代谢药物作为初始治疗。
- 药物选择(口服或静脉双膦酸盐、地舒单抗或甲状旁腺激素类似物)应通过共享决策制定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective is to update recommendations for prevention and treatment of glucocorticoid-induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily. METHODS: An updated systematic literature review was performed for clinical questions on nonpharmacologic, pharmacologic treatments, discontinuation of medications, and sequential therapy. Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the certainty of evidence. A Voting Panel achieved ≥70% consensus on the direction (for or against) and strength (strong or conditional) of recommendations. RESULTS: For adults beginning or continuing >3 months of GC treatment, we strongly recommend as soon as possible after initiation of GCs, initial assessment of fracture risks with clinical fracture assessment, bone mineral density with vertebral fracture assessment or spinal x-ray, and Fracture Risk Assessment Tool if ≥40 years old. For adults at medium, high, or very high fracture risk, we strongly recommend pharmacologic treatment. Choice of oral or intravenous bisphosphonates, denosumab, or parathyroid hormone analogs should be made by shared decision-making. Anabolic agents are conditionally recommended as initial therapy for those with high and very high fracture risk. Recommendations are made for special populations, including children, people with organ transplants, people who may become pregnant, and people receiving very high-dose GC treatment. New recommendations for both discontinuation of osteoporosis therapy and sequential therapies are included. CONCLUSION: This guideline provides direction for clinicians and patients making treatment decisions for management of GIOP. These recommendations should not be used to limit or deny access to therapies.
引用
- Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care Res (Hoboken). 2023. PMID: 37884467. doi:10.1002/acr.25240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。